Advertisement
"We are honored that the scientific community has recognized EMD Serono asa leading place to work," said Bernhard Kirschbaum, PhD, Executive VicePresident, Research, Merck Serono. "Our success as a leader within thebiopharmaceutical industry is a direct result of the hard work, passion anddedication of our employees. We are committed to creating an environment forour scientists that fosters growth, professional development and a place whereintellectually curious people can thrive and grow with a common goal offinding new treatments for unmet medical needs."
Advertisement
This is the second time EMD Serono has been placed on Science magazine'sTop Employer survey; previously the organization ranked number 17.
The survey sought to determine which biotechnology and pharmaceuticalcompanies were most admired by people who work in the field, and why. Surveyrespondents also rated the companies on 23 different attributes, whichincluded Corporate Image, Financial Prowess, Leadership and Direction,Work/Culture Environment, Location and Academic and Intellectual Challenge.The methodology used for the survey included email invitations to AAASmembers, Science Careers registrants, and Science website visitors.
The ranking is a result of a survey conducted by Science magazine, alongwith the American Association for the Advancement of Science (AAAS), andcommissioned by Senn-Delaney Culture Diagnostics and Measurement to conduct aweb-based survey aimed at determining the companies in the biotechnology andpharmaceutical industries with the best reputations as employers.
About EMD Serono, Inc.
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is aleader in the US biopharmaceutical arena, integrating cutting-edge sciencewith unparalleled patient support systems to improve people's lives. Thecompany has strong market positions in neurodegenerative diseases, withRebif(R) (interferon beta-1a), as well as in endocrinology, with Saizen(R)(somatropin (rDNA origin) for injection), Serostim(R) (somatropin (rDNAorigin) for injection) and Zorbtive(TM) (somatropin (rDNA origin) forinjection). EMD Serono is a leader in fertility treatments, with Gonal-f(R)(follitropin alpha for injection), Luveris(R) (lutropin alfa for injection)and Ovidrel(R) Prefilled Syringe (choriogonadotropin alpha injection). With aclear focus on the patient and a leadership presence in the biopharmaceuticalindustry, EMD Serono's US footprint continues to grow, with more than 950employees around the country and fully integrated commercial, clinical andresearch operations in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com
About Merck KGaA
Merck is a global pharmaceutical and chemical company with total revenuesof EUR 7.1 billion in 2007, a history that began in 1668, and a future shapedby 30,968 employees in 60 countries. Its success is characterized byinnovations from entrepreneurial employees. Merck's operating activities comeunder the umbrella of Merck KGaA, in which the Merck family holds anapproximately 70% interest and free shareholders own the remainingapproximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriatedand has been an independent company ever since.
For more information, please visit www.merckserono.net or www.merck.de
SOURCE EMD Serono, Inc.
